IMMX Reports 95% Complete Response Rate in NEXICART-2 Trial for Relapsed/Refractory AL Amyloidosis, Plans Phase 3 Trial Initiation
Immix Biopharma, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $9.22
+1.3% in 1d after detection
Post-detection moves
1h
—
1d
+1.3%
3d
+0.7%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS